Deutsche Bank initiated coverage of Immunocore (IMCR) with a Buy rating and $65 price target The firm says Kimmtrak has established itself as the standard of care for HLA-A*02+ front-line metastatic uveal melanoma with its overall survival benefit. Immunocore’s current valuation offers a favorable risk/reward where Kimmtrak’s “niche” in metastatic uveal melanoma provides a “floor valuation” with expansion into second-line cutaneous melanoma providing upside, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMCR:
- Immunocore Holdings Secures Shareholder Approval at AGM
- Immunocore price target raised to $86 from $85 at Oppenheimer
- Immunocore Holdings Reports Strong Q1 2025 Performance
- Immunocore price target lowered to $52 from $66 at Barclays
- Immunocore Holdings: Strong Sales Growth and Financial Position Justify Buy Rating